Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases. Prospective Data After Five Years of Follow Up

Maria Auxiliadora Martin-Martinez¹, Santos Castañeda², Fernando Sanchez-Alonso³, Carmen García-Gómez⁴, Carlos González_Juanatey⁵, M. Ángeles Belmonte-López⁶, Jesus Tornero-Molina⁷, José Santos-Rey⁸, Carmen Olga Sánchez-González⁹, Estefania Moreno¹⁰, Maria del puerto Moreno-Gil¹¹, Tatiana Cobo-Ibañez¹², Jose Antonio Pinto-Tasende¹³, Jesús Babío-Herráez¹⁴, Gema Bonilla¹⁵, Antonio Juan-Mas¹⁶, Francisco Manero-Ruiz¹⁷, Montserrat Romera-Baurés¹⁸, Javier Bachiller-Corral¹⁹, Eugenio Chamizo-Carmona²⁰, Javier Calvo-Catalán²¹, Raimon Sanmartí²², Celia Erausquin-Arruabarrena²³, Rosario Garcia-Vicuña²⁴, Carmen Barbadillo²⁵, Sergio Ros-Expósito²⁶, Ana Isabel Turrión²⁷, M José González-Fernández²⁸, Jose Miguel Senabre²⁹, Silvia Martínez-Pardo³⁰, Ana Ruibal-Escribano³¹, Emilio Giner-Serret³², Elisabet Berzosa-Sola³³, Julia Martínez-Barrio³⁴, Encarnación Pagán³⁵, M Enriqueta- Peiró³⁶, Sagrario Bustabad-Reyes³⁷, Alba Erra-Durán³⁸, Beatriz González Álvarez³⁹, Ana Cruz Valenciano⁴⁰, Javier Rivera-Redondo⁴¹, Manuel Moreno Ramos⁴², Sergio Rodriguez Montero⁴³, Mercedes Morcillo-Valle⁴⁴, Maria Teresa Navío⁴⁵, Maria Galindo-Izquierdo⁴⁶, Manuel Riera-Soler⁴⁷, Jordi Fiter⁴⁸, Javier Llorca⁴⁹ and Miguel Ángel González-Gay⁵⁰, ¹Spanish Society of Rheumatology, Madrid, Spain, ²Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ³Biobadaser, Research Unit, Sociedad Española de Reumatología, Madrid, Spain, ⁴Consorci Sanitari de Terrassa, Barcelona, Spain, ⁵Hospital Lucus Augusti, Lugo, Spain, ⁶Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁷University Hospital of Guadalajara. Spain, Madrid, Madrid, Spain, ⁸Hospital Virgen de la Salud, Toledo, Spain, ⁹Hospital Sureste, Madrid, Spain, ¹⁰Universitario Vall D'hebron, Barcelona, Spain, ¹¹Complejo Hospitalario de Cáceres, Caceres, Spain, ¹²Hospital Infanta Sofia, Madrid, Spain, ¹³CHUAC, A Coruña, Spain, ¹⁴Hospital de Cabueñes, Gijón, Spain, ¹⁵Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ¹⁶Hospital Sont Llatzer, Palma de Mallorca, Spain, ¹⁷Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁸Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁰Hospital de Merida, Badajoz, Spain, ²¹Hospital General Universitario Valencia, Valencia, Spain, ²²Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ²³Hospital de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ²⁴Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ²⁵Hospital Universitario Puerta de Hierro, Madrid, Spain, ²⁶Hospital Viladecans, Barcelona, Spain, ²⁷Hospital Universitario de Salamanca, Salamanca, Spain, ²⁸Hospital Dexeus, Barcelona, Spain, ²⁹Hospital de Marina Baixa, Alicante, Spain, ³⁰H. Mutua de Terrassa, Barcelona, Catalonia, Spain, ³¹Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ³²Hospital Obispo Polanco, Teruel, Spain, ³³Hospital del Elda, Alicante, Spain, ³⁴Hospital General Universitario Gregorio Marañón, Madrid, ³⁵Hospital Los Arcos, Murcia, Spain, ³⁶Hospital Marques de Valdecilla, Santander, Spain, ³⁷Hospital Universitario Canarias, Tenerife, Spain, ³⁸Hospital San Rafael, Barcelona, Spain, ³⁹Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain, ⁴⁰Hospital Severo Ochoa, Madrid, Spain, ⁴¹Instituto Provincial de Rehabilitación, Madrid, Spain, ⁴²Hospital Virgen de la Arrixaca, Murcia, Spain, ⁴³H. Virgen de Valme, Sevilla, Spain, ⁴⁴Hospital El Escorial, Madrid, Spain, ⁴⁵Hospital Infanta Leonor, Madrid, Spain, ⁴⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴⁷Hospital dos de Maig, Barcelona, Spain, ⁴⁸Hospital Universitario Son Dureta, Palma de Mallorca, Spain, ⁴⁹School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ⁵⁰Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

Meeting: ACR Convergence 2020

Keywords: Cardiovascular, Psoriatic arthritis, rheumatoid arthritis, Spondylarthropathies, spondyloarthritis

Session Information

Date: Saturday, November 7, 2020

Title: Epidemiology & Public Health Poster II: OA, Osteoporosis, & Other Rheumatic Disease

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To determine the incidence and risk factors implicated in the development of first cardiovascular (CV) event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD) attending Spanish rheumatology clinics after 5 years of follow-up.

Methods: Analysis of data of patients included in an observational prospective study [CARdiovascular in rheuMAtology (CARMA) project] after 5 years of follow-up. The study includes a cohort of patients with CIRD [rheumatoid arthritis (RA, n=775, ankylosing spondylitis (AS, n=738), and psoriatic arthritis (PsA, n=721)], and another cohort of matched individuals (n=677) without CIRD attending outpatient rheumatology clinics from 67 public hospitals in Spain. Cumulative incidence per 1000 patients of CVE was estimated in both cohorts at 5 years from the start of the project. Weibull proportional hazard model was used to calculate the Hazard Ratio (HR) and 95% confidence intervals (95% CI) of the risk factors involved in the development of CV events. Losses to follow-up and their causes were also analyzed.

Results: The total number patient who completed the follow-up visit at 5 years was 2.382 (81.9% of those who started the study). Fifteen patients died due to CVE and sixty due to non-CVE. Cardiovascular cumulative incidence of CVE in patients with CIRD was higher in PsA patients (48.9; 95% CI: 40.7-57.1). The higher risk of developing a first CVE during the 5 years of follow-up was seen in patients with AS (HR: 4.60 ; 95% CI: 1.32-15.99; p=0.02), those with older age (HR:1.09; 95% CI: 1.05-1.13; p< 0.001), higher systolic blood pressure (HR: 2.64; 95% CI: 1.32-5.25; p=0.006), and those with longer duration of the rheumatic disease (HR: 1.07; 95% CI: 1.03-1.12; p=0.002). In contrast, woman gender was a protective factor (HR: 0.45; 95% CI: 0.21-0.99; p=0.047).

Conclusion: Patients with AS prospectively followed-up at rheumatology outpatient clinics showed higher risk of developing a CVE than those with RA or PsA. Besides traditional CV disease risk factors, a longer time course of the disease is a risk factor for the development of CV disease in patients with CIRD.

Disclosure: M. Martin-Martinez, None; S. Castañeda, Roche, 2; F. Sanchez-Alonso, None; C. García-Gómez, None; C. González_Juanatey, None; M. Belmonte-López, None; J. Tornero-Molina, None; J. Santos-Rey, None; C. Sánchez-González, None; E. Moreno, None; M. Moreno-Gil, None; T. Cobo-Ibañez, None; J. Pinto-Tasende, None; J. Babío-Herráez, None; G. Bonilla, None; A. Juan-Mas, None; F. Manero-Ruiz, None; M. Romera-Baurés, None; J. Bachiller-Corral, None; E. Chamizo-Carmona, None; J. Calvo-Catalán, None; R. Sanmartí, None; C. Erausquin-Arruabarrena, None; R. Garcia-Vicuña, BMS, 2, 5, 8, Lilly, 2, 5, 8, MSD, 2, 9, Novartis, 2, 9, Roche, 2, Abbvie, 5, 9, Biogen, 5, Celltrion, 5, Gebro, 5, Mylan, 5, Pfizer, 2, 5, 9, Sandoz, 2, 5, 8, Sanofi, 5, 8, 9; C. Barbadillo, None; S. Ros-Expósito, None; A. Turrión, None; M. González-Fernández, None; J. Senabre, None; S. Martínez-Pardo, None; A. Ruibal-Escribano, None; E. Giner-Serret, None; E. Berzosa-Sola, None; J. Martínez-Barrio, None; E. Pagán, None; M. Peiró, None; S. Bustabad-Reyes, None; A. Erra-Durán, None; B. González Álvarez, None; A. Cruz Valenciano, None; J. Rivera-Redondo, None; M. Moreno Ramos, None; S. Rodriguez Montero, None; M. Morcillo-Valle, None; M. Navío, None; M. Galindo-Izquierdo, None; M. Riera-Soler, None; J. Fiter, None; J. Llorca, None; M. González-Gay, None.

To cite this abstract in AMA style:

Martin-Martinez M, Castañeda S, Sanchez-Alonso F, García-Gómez C, González_Juanatey C, Belmonte-López M, Tornero-Molina J, Santos-Rey J, Sánchez-González C, Moreno E, Moreno-Gil M, Cobo-Ibañez T, Pinto-Tasende J, Babío-Herráez J, Bonilla G, Juan-Mas A, Manero-Ruiz F, Romera-Baurés M, Bachiller-Corral J, Chamizo-Carmona E, Calvo-Catalán J, Sanmartí R, Erausquin-Arruabarrena C, Garcia-Vicuña R, Barbadillo C, Ros-Expósito S, Turrión A, González-Fernández M, Senabre J, Martínez-Pardo S, Ruibal-Escribano A, Giner-Serret E, Berzosa-Sola E, Martínez-Barrio J, Pagán E, Peiró M, Bustabad-Reyes S, Erra-Durán A, González Álvarez B, Cruz Valenciano A, Rivera-Redondo J, Moreno Ramos M, Rodriguez Montero S, Morcillo-Valle M, Navío M, Galindo-Izquierdo M, Riera-Soler M, Fiter J, Llorca J, González-Gay M. Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases. Prospective Data After Five Years of Follow Up [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/incidence-of-first-cardiovascular-event-in-spanish-patients-with-chronic-inflammatory-rheumatic-diseases-prospective-data-after-five-years-of-follow-up/. Accessed .

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-of-first-cardiovascular-event-in-spanish-patients-with-chronic-inflammatory-rheumatic-diseases-prospective-data-after-five-years-of-follow-up/